MKI67 and neoplasm: Therapeutic selection was guided by molecular profiling and tumour characteristics, particularly the NGS results from liver and peritoneal metastases, which revealed: PD-L1 expression of 15%, presence of the EWSR1/CREB1 fusion, no other actionable oncogenic drivers, and a Ki-67 index of 30%.